Europe Allergy Treatment Market is expected to reach US$ 10,424.97 Mn by 2028

PRESS RELEASE BY The Insight Partners 04 May 2021

Share this press on

The rhinitis segment by allergy type is estimated to lead the market growth during the forecast period.

According to The Insight Partners market research study of “Europe Allergy Treatment Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Allergy Type, Treatment and Country.” The Europe allergy treatment market is expected to reach US$ 10,424.97 million by 2028 from US$ 6,036.60 million in 2020, it is estimated to grow at a CAGR of 7.1% from 2021 to 2028. The report highlights trends prevailing in the Europe allergy treatment market and the factors driving market along with those that act as hindrances.

The Europe Allergy treatment market, based on the allergy type was segmented into eye allergy, rhinitis, asthma, skin allergy, food allergies, and other allergies. In 2020, the rhinitis segment held the largest share of the market, whereas the food allergies segment is expected to grow at the fastest rate during the coming years. The allergies are hypersensitive responses from human immune system to the substance that are foreign to the body. While allergies can disturb the normal functioning of organs, severe allergies can be life threatening; for example, asthma leads to poor lung functioning. Although the most effective method of gaining protection against allergies is to avoid being exposed to the known allergens, medications such as steroids and antihistamines are available for treating them. According to a European survey in 2019, in Europe, the prevalence of allergic rhinitis ranges from 17 to 29%, whereas the prevalence of asthma varies from 1.3 to 11% among children and adults. Immunotherapy has shown positive and long-term benefits in allergic patients. In addition, it is suitable for self-administration and medicine usage in homecare settings. Therefore, immunotherapy has emerged as a safe and effective alternative subcutaneous route for both chronic and recurrent allergies. Also, developments in the pharmaceuticals industry have enabled companies to offer treatment for varied allergy reactions. Such developments in the food allergy treatment options and their effectiveness boost the growth of the Europe allergy treatment market.

The rapid growth of COVID-19 cases in Europe has had a major impact on the European economy. Amid COVID-19 outbreak pandemic, it is discovered that a significant number of people across the world are suffering from chronic respiratory diseases such as respiratory allergies, allergic rhinitis, and sinusitis. EAACI, in collaboration with ARIA, in Europe has provided recommendations on operational plans and practical procedures for ensuring optimal standards in the daily clinical care of patients affected by allergic diseases. Therefore, the growing demand for allergy treatments in Europe boosts the growth of the allergy treatment market in the region.

The growth of the market is attributed to increasing adoption of immunotherapy in allergy treatment, and developments in food allergy treatments. However, the lack of awareness about allergy treatments is a key factor restraining the market growth.

LETI Pharma, Dermapharm Holding Se, Johnson and Johnson Services, Inc., Sanofi, AbbVie's Inc., Pfizer, ALK-Abelló A/S, Allergy Therapeutics, Stallergenes Greer and GlaxoSmithKline PLC are among the leading companies operating in the Europe allergy treatment market.

The report segments in Europe Allergy Treatment Market as follows:

By Allergy Type:

  • Eye Allergy
  • Rhinitis
  • Asthma
  • Skin Allergy
  • Food Allergies
  • Other Allergies

By Treatment:

  • Anti-Allergy Drugs
    • Antihistamines
    • Corticosteroids
    • Decongestants
    • Other Drugs
  • Immunotherapy
    • Sub-cutaneous Immunotherapy (SCIT)
    • Sub-Lingual Immunotherapy (SLIT)

By Country

  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe

Contact Us
Phone: +1-646-491-9876
Email Id:
Download Free PDF Brochure